INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide [1] , with an estimated prevalence of 20-30%in general population and 75% in patients with type 2 DM, obesity and metabolic syndrome [2, 3] . NAFLD is a pathological condition characterized by aberrant triglycerides accumulating in the hepatocytes, in some cases accompanied by necro-inflammatory activity and fibrosis (steatohepatitis) and potentially evolving into liver cirrhosis [4] . However, beside lifestyle intervention, no established therapy of NAFLD has been identified yet [5] . Non-alcoholic fatty liver disease is the hepatic component of metabolic syndrome where the insulin resistance increases non esterified fatty acids release from adipose tissue and favor their deposition into hepatocytes [6] .
Low vitamin D levels have been associated with the histological severity of NAFLD/NASH [7] . Overall, a 26 % additional risk for vitamin D deficiency has been reported in NAFLD subjects [8] So, the aim of the present study was to evaluate the effect of vitamin D supplementation on specific sub-populations of patients with fatty liver not studied in the previous trials, namely NAFLD patients with moderate to severe liver disease. To be eligible for the study, patients had to satisfy the following criteria: fatty liver detected by abdominal ultrasonography (US) and confirmed by histopathology, ALT is more than AST, negative tests for HBsAg and HCV Abs.
PATIENTS AND METHODS

Exclusion criteria include :
History of alcohol abuse (as defined by an average daily consumption of alcohol >30 g/day in men and >20 g/day in women), cirrhosis, autoimmune hepatitis and other causes of liver disease (hemochromatosis, Wilson's disease), hyper/ hypoparathyroidism, known hypersensitivity to cholecalciferol, hypercalcemia, hypercalciuria, nephrolithiasis, nephrocalcinosis.
All patients were subjected to: 1-Thorough history taking with full clinical examination and all medications were carefully recorded at baseline visits and drug alterations regarding anti-diabetic agents, anti-hypertensive treatments. Statins were not allowed throughout the study.
2-The body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters.
3-Serum 25 (OH)-cholecalciferol was measured as an indicator of vitamin D status [16].
4-Liver ultrasound scanning was performed to assess the presence of hepatic steatosis.
5-Evaluation of lipid profile (LDL, HDL, triglycerides), glycemic control (HbA1c %) and liver enzymes (ALT, AST) before and after vitamin D supplementation.
6-Liver biopsy for all patients at base line, to confirm the diagnosis and for histological grading of NAFLD, using Kleiner NAFLD activity score (NAS). This score is the sum of three histological components; steatosis (0-3), lobular inflammation (0-3) and ballooning degeneration (0-2). It ranges from 0 to 8
7-Vitamin D supplementation in the form of oral solution of cholecalciferol (50,000 IU/week) for 24 weeks for both groups. 
Statistical Analysis
Ethical Considerations
Since the patients have elevated liver enzymes with no obvious cause, some patients had family history of liver diseases and liver malignancy and imaging evident of focal fat and focal sparing, liver biopsies were done to detect the underlying cause and written consent was obtained from all patients before the study.
The study protocol was reviewed and approved by the Institutional Review Board of the faculty of Medicine, Zagazig University, Egypt. After 24 weeks of vitamin D supplementation, there was statistically significant improvement in LDL, HDL, triglycerides, ALT and AST in group I (Table 2) , while there was non-significant change in group II (Table 2) .
RESULTS
Out
Finally, it was noted that at baseline there was non-significant difference between both groups regarding the anti-inflammatory marker (CRP); 3.4±1.3 vs. 3.4±1.3, p value 0.213. After vitamin D supplementation there was statistically significant improvement of CRP in both populations.
When comparing both groups after vitamin D supplementation, there were non-significant differences regarding hepatic indicators, lipid profile and HbA1c%, but there were significant differences in CRP (Table 3) .
Moreover, we performed a correlation analysis that showed a significant association between NAFLD scores, serum 25(OH)-cholecalciferol levels, lipid profile and histological grading (Table 4 ). In this study, all subjects affected by NAFLD have sub-optimal serum 25 (OH)-cholecalciferol levels compared to age and sex matched subjects (data not shown); however, subjects with deficient levels display a significantly more severe liver disease than those with sufficient levels. Previously, an association between low 25 (OH)-cholecalciferol levels and the histological severity of NASH was suggested by Targher et al. [7] .
In this study, participants were recruited among patients referred to hepatology clinic. This allowed selection of patients with more severe liver disease as compared to those studied in previous trials [14, 15] . The baseline biochemical tests as well as the histological activities were significantly different among study populations. 
CONCLUSION
Correction of hypovitaminosis D may has beneficial effects in NAFLD patients with moderate to severe activity, while vitamin D supplementation has no effect on NAFLD patients with sufficient vitamin D level. Larger, randomized, placebocontrolled trials are required to better evaluate the efficacy of vitamin D supplementation on NAFLD.
